-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-07-30
Gensci's VEGFR2 mAb NDA Accepted by NMPALearn More
-
2026-07-30
GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical TrialsLearn More
-
2025-02-10
Clinical Trial Commencement of GenSci120 Injection ApprovedLearn More
-
2025-01-22
GenSci Showcases the Latest R&D Achievements at J.P. MorganLearn More
-
2025-01-17
NMPA Approves the PD-1 agonist GenSci120 for Clinical Trials CommencementLearn More
-
2024-12-12
GenSci Invites You to Meet Us at Arab Health 2025Learn More
-
2024-11-20
Chinese Monoclonal Anti-IL-1β Breakthrough: Acute Gout Arthritis Treatment Impresses at ACR 2024Learn More
-
2024-11-11
World ADC San Diego 2024: GenSci showcases two innovative pipeline programsLearn More